Kallikrein-kinin system activation and its interactions with other plasma haemostatic components in the coronary artery disease.
Concentrations of kininogens, prekallikrein, fibrinogen and antigens of protease inhibitors as well as kininase, fibrinolytic and antipapain activities were estimated in blood plasma (or serum) of patients with coronary artery disease (CAD) before and after the exercise test. The study was conducted on 44 subjects with chronic, stable CAD and 54 myocardial infarction patients (15 treated with streptokinase and 39 subjected to primary percutaneous transluminal coronary angioplasty, PTCA). The patients were divided into two subgroups: treated and untreated with angiotensin I-converting enzyme inhibitor (ACE-I), enalapril. Activation of the fibrinolytic system and the prekallikrein during the exercise test was demonstrated. No significant kininogen consumption was observed. A decrease in kininase activity was found. The results suggest the possibilities of endothelial cells contribution to plasminogen activation in CAD patients. Kininogen and kallikrein directly, or through the released kinins, may participate in regulation of endothelial cell hemostatic functions. Conversion of plasminogen to plasmin may undergo under the influence of kallikrein. The bradykinin induces the tissue plasminogen activator (t-PA) secretion, which depends also on the increased blood flow during the exercise test.
Czokało-Plichta
M
M
Department of General and Experimental Pathology, Medical Academy of Białystok, Białystok, Poland.
Skibinska
E
E
Kosiorek
P
P
Musiał
W J
WJ
D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D016022:Case-Control Studies; D003324:Coronary Artery Disease / Q000097:blood* / Q000628:therapy; D004656:Enalapril / Q000627:therapeutic use; D005080:Exercise Test; D005260:Female; D006487:Hemostasis; D006801:Humans; D016234:Kallikrein-Kinin System / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000628:therapy
D000806:Angiotensin-Converting Enzyme Inhibitors; D004656:Enalapril